Recap: Esperion Therapeutics Q4 Earnings

By Benzinga4 days ago

Shares of Esperion Therapeutics (NASDAQ:ESPR) decreased after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were down 72.12% over the past year to ($3.89), which missed the estimate of ($3.76).

Revenue of $9,638,000 up by 881.47% year over year, which missed the ...

Full story available on Benzinga.com

Continue read on benzinga.com